Company Overview and News


Add GSK
to your dashboard

Headline News

Why is Puma (PBYI) Stock Up More than 150% in a Year's Time?

2h zacks
Shares of Puma Biotechnology, Inc. (PBYI - Free Report) have significantly outperformed the industry in a year. The stock has skyrocketed 186.4% compared with the industry’s increase of 3.3% during the period. (52-0)

2018 Strategic Outlook: Will Fortune Favor The Bold In Biotech?

2h seekingalpha
Significant scientific and technological breakthroughs, combined with unabated M&A appetite and tax reform, provide fertile ground for biotech gains in 2018. (302-0)

Dynavax Makes Its Case To Investors

6h seekingalpha
Dynavax CEO Gray presented at an investor conference on January 11, discussing the commercial launch of Heplisav-B, as well as progress in the immuno-oncology pipeline. (40-0)

Dynavax: Gearing Up For Its Next Big Run

2018-01-15 seekingalpha
Dynavax's (NASDAQ:DVAX) share price tells its own morality tale. It rises to the heavens and then crashes to the shades below. After doubling in price to ~$30 on optimism over its HEPLISAV-B vaccination during the first three quarters of 2015, it then crashed to below $5.00 to start 2017 in response to HEPLISAV-B's CRL saga at the FDA. (40-0)

Glaxo's Influenza Vaccine Gets FDA Nod for Label Expansion

2018-01-15 zacks
GlaxoSmithKline plc (GSK - Free Report) received approval from the FDA’s Center for Biologics Evaluation and Research for the label expansion of influenza vaccine — FluarixQuadrivalent. The vaccine has been approved for infants six months or older.  (59-0)

Your Daily Pharma Scoop: Lipocine's Gloomy Future, Puma Labeling Change, Concert's Mixed Day

2018-01-13 seekingalpha
Puma plans to modify labeling in its European marketing application for its breast cancer candidate neratinib. (254-4)

Analysis: Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-13 in.reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Drugmakers see a pricing blueprint in an $850,000 gene therapy

2018-01-12 reuters
SAN FRANCISCO (Reuters) - Global drugmakers are looking to a tiny biotech’s $850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Drugmakers see a pricing blueprint in an US$850,000 gene therapy - Channel NewsAsia

2018-01-12 channelnewsasia
SAN FRANCISCO: Global drugmakers are looking to a tiny biotech's US$850,000 therapy for a rare type of blindness as a model for getting paid for highly expensive – and effective – new medicines. (45-0)

Pharma Stock Roundup: Novo Nordisk Reveals Bid to Acquire Ablynx, Pfizer & Others at Healthcare Conference

2018-01-12 zacks
Focus this week was on the 36th annual JPMorgan healthcare conference where several biotech and pharma companies provided a preliminary look at their results for 2017 and also provided pipeline updates as well as their outlooks for 2018. Recap of the Week’s Most Important Stories Key Takeaways from JPMorgan Healthcare Conference: Several pharma companies were present at the 36th annual JPMorgan healthcare conference, the largest and most informative healthcare investment symposium in the industry. (18-0)

AstraZeneca's Asthma Drug Benralizumab Gets Approval in EU

2018-01-11 zacks
AstraZeneca, plc (AZN - Free Report) announced that the European Commission (“EC”) has granted approval to its asthma disease candidate, benralizumab. It is approved as an add-on maintenance treatment for severe eosinophilic asthma in adult patients. It will be marketed by the trade name of Fasenra. (344-0)

EU Launches $1.2 Billion Supercomputing Plan, Without U.K. - Bloomberg

2018-01-11 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (5-0)

Exelixis - Looking Good For 2018

2018-01-11 seekingalpha
Wider treatment options of this drug and continued growth should fuel product revenue growth, as the research pipeline looks strong as well. (39-0)

Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar

2018-01-10 zacks
Novartis AG (NVS - Free Report) initiated a head-to-head trial, SURPASS, on psoriasis drug, Cosentyx. The drug will be compared to its proposed biosimilar for the treatment of ankylosing spondylitis (AS). (145-0)

G1 Therapeutics: Undervalued With Upcoming Catalysts

2018-01-10 seekingalpha
I look favorably on their collaborations with AstraZeneca and Genentech, which add more credibility to the bullish thesis. (108-3)

CUSIP: 37733W105